Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)

Next Previous
Trial Profile

A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; Clear cell sarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Meningioma; Myxoid liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Perivascular epithelioid cell tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 24 Apr 2023 Status changed from active, no longer recruiting to completed.
  • 29 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
  • 12 Feb 2021 Planned End Date changed from 1 Mar 2023 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top